Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
6 min read
Crizanlizumab Biologics Sequence Review Report 2026: P-selectin Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Crizanlizumab, an antibody targeting P-selectin.
6 min read
Inclacumab Biologics Sequence Review Report 2026: P-selectin Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Inclacumab, an antibody targeting P-selectin.
6 min read
Caplacizumab Biologics Sequence Review Report 2026: von Willebrand factor Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Caplacizumab, a nanobody targeting von Willebrand factor.
6 min read
Emicizumab Biologics Sequence Review Report 2026: Factor IXa/Factor X Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emicizumab, a bispecific antibody targeting Factor IXa/Factor X.
6 min read
Marstacimab Biologics Sequence Review Report 2026: TFPI Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Marstacimab, an antibody targeting TFPI.
6 min read
Concizumab Biologics Sequence Review Report 2026: TFPI Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Concizumab, an antibody targeting TFPI.
6 min read
Garadacimab Biologics Sequence Review Report 2026: Factor XIIa Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Garadacimab, an antibody targeting Factor XIIa.
6 min read
Narsoplimab Biologics Sequence Review Report 2026: MASP-2 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Narsoplimab, an antibody targeting MASP-2.
6 min read
Sutimlimab Biologics Sequence Review Report 2026: C1s Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sutimlimab, an antibody targeting C1s.
6 min read
Crovalimab Biologics Sequence Review Report 2026: C5 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Crovalimab, an antibody targeting C5.
6 min read
Pozelimab Biologics Sequence Review Report 2026: C5 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pozelimab, an antibody targeting C5.
6 min read
Ravulizumab Biologics Sequence Review Report 2026: C5 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ravulizumab, an antibody targeting C5.